美股A股
StockGist
Back
10-Q2026-05-14· qwen-plus

CYPH · Leap Therapeutics, Inc.

0001104659-26-060662

SEC filing

Summary

Operating performance improved meaningfully year-over-year, with operating income narrowing to -$4.8M from -$15.9M, but net loss widened sharply to -$77.2M due to a large non-cash unrealized loss tied to the company’s new digital asset treasury strategy.

Key takeaways

Full analysis

Operating Performance

Operating income improved to -$4.8 million for the three months ended March 31, 2026, compared to -$15.9 million for the same period in 2025. This improvement was primarily due to the completion of clinical trials and the Company’s reduction in force in June 2025, which significantly lowered research and development expenses. These operational changes reflect a strategic shift toward cost discipline following key clinical milestones.

Net Loss and Non-Cash Impact

Net loss for the quarter was -$77.2 million, compared to -$15.4 million in the prior-year period. The substantial increase in net loss was driven by a $77.6 million non-cash unrealized loss on embedded derivative valuation — directly attributable to the digital asset treasury strategy launched in October 2025. As disclosed in Management’s Discussion, this strategy deploys capital not required for ongoing operations into digital assets, exposing earnings to market-driven valuation fluctuations without corresponding cash flow impact.

Cash Flow from Operations

Earnings Per Share

Diluted EPS was -$0.46 for Q1 FY2026, compared to -$0.37 for Q1 FY2025. The decline aligns with the increased net loss magnitude and reflects no material change in weighted-average diluted shares outstanding outside of routine equity activity.

Forward-Looking Context

Management reiterates that operating losses are expected to continue for the foreseeable future. The Company also cautions that without additional funding or development program cost-sharing, it may be forced to eliminate certain programs, reduce discretionary expenses, or delay expansion — all of which could adversely affect business prospects. This outlook is reinforced by anticipated increases in general and administrative expenses as the Company expands headcount and incurs higher compliance, audit, legal, and investor relations costs associated with its public-company status and digital asset strategy.